Advisory Board

Professor Daniel Cebo

Daniel Cebo, Ph.D. is a molecular biologist, lecturer, author, and life sciences entrepreneur. He is an Independent Investigator, Honorary Professor, and Scientific Advisor with the Human Acumen Initiative.

Daniel is a critical and disputatious scientist with interests in science, technology, and health, and whose current focuses are on synthetic biology, robots, artificial intelligence, and the future of humanity.

Daniel coauthored Application of cyborgs and enhancement technology in biomedical engineering and authored CYBERBIOSECURITY: Can We Hack the Human Body?, Is a New Age of Enlightenment on the Horizon?: A Decade of Infinite Possibilities and Exponential Life, Life 4.0 – Our Final Discovery, Cyberbiosecurity, Big Data: A Twenty-First Century Arms Race, Human Cloning and Stem Cells, Human pluripotent stem cells: Engineering tissue from human embryonic stem cells, Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy, and Transport Ammonium across Prokaryotic Membranes.

His main area of research is the development of general theoretical, computational, and experimental methods in relation to medicine and human biological science. Daniel has developed two laboratory and three computer-based methods and concepts for monitoring, identifying, and quantifying infections and methods and principles for the prevention and control of infectious diseases.

His second area of research is the transformation of stem cell biology into stem cell medicine. He covers molecular and cellular approaches to stem cell research and includes stem cell bio-engineering, gene delivery systems, and molecular virology with applications in regenerative medicine and tissue engineering.

The third area of Daniel’s research interests lies in the relationship between substance abuse and HIV / AIDS. He examines HIV knowledge, perceived risk, and HIV testing among drug users in Germany. For this purpose, Daniel uses quantitative and qualitative techniques, interviews, and agency records to analyze several hypotheses related to improving the implementation of drug abuse and HIV services for offenders. More precisely, Daniel is working on the production of two computer-simulated tools (in silico tests) to support future risk assessments of new psychoactive substances.

Read Crystal Meth and HIV/AIDS:A Pilot Study of Behavioral and Clinical Correlates and Future of Psychoactive Drugs in the Time of Cutting-Edge Technologies.

Between 2019 and 2021, Daniel was Research Affiliate at the Postdoctoral Institute for Computational Studies (PICompS), a virtual home for both independent and academic researchers.

Previously he was Scientific Officer at the Enterprise Science Platform OmicX working on biorobotics and high-throughput techniques, computational biology, emerging infectious diseases, and digital drug discovery.

From 2015 until 2017, Daniel was Research Scientific Director at the Center for Infectious Diseases where he also worked on promotional and scientific content management, molecular diagnostics, HIV/AIDS management, and health services research.

Daniel became Research Assistant at Albert-Ludwigs-Universität Freiburg, Germany in 2007 working on proteomics, X-ray crystallography, bioinformatics and systems biology, and structural analysis. There he earned his Ph.D. in Biochemistry, Biophysics, and Molecular Biology in 2010.

He earned his Bachelor’s Degree of Science in Molecular Biology and Physiology in 2003 from the University of Belgrade.

He began his career as a researcher in molecular biology, neurology, and biomedicine. In 2005 until 2007, Daniel was Scientific Associate at the Hertie Institute for Clinical Brain Research where he also developed a research interest in stem cell research and community-based research, particularly in global health and substance abuse.

After completing his Ph.D., Daniel decided to use his experience and scientific background to conduct research on emerging technologies to provide scientific evidence and advice to policy makers and international institutions around the world.

In 2010, he joined the Max Planck Institute for Dynamics of Complex Technical Systems as Science Laboratory Manager working on lab-on-a-chip technology and its applications, artificial intelligence and robotics, and additive manufacturing for biomedical Systems.

For four years, he was Principal Scientist and Academic Lecturer and worked on education research, stem cells and tissue engineering, academic lecturing, and regenerative medicine and biomaterials at Freie Universität Berlin until 2015.

His work continues in the areas of emerging technological challenges, scientific diplomacy, scientific controversy, forecasting, and global risk management such as the use of artificial intelligence, bioweapons, human engineering, immortality, gene therapy, and human-engineered pandemics.

Daniel is dedicated to increasing public awareness of science through frequent online and public speaking engagements and popular science publications. He argues about the future of humanity, as he believes the long-term results for our civilization depend on how we deal with the introduction of certain transformative and digital human-machine capabilities.

He was an invited speaker at the Conference of Artificial Intelligence in Medicine (2019), Advances in Cell and Tissue Culture Symposium (2019), Annual Meeting of the Society for Virology (2018), and the International Stem Cell Conference (2015).

Read Scientific Relevance and Future of Digital Immortality and Virtual Humans.

Visit his LinkedIn profile, Amazon page, ResearchGate profile, and Publons profile. Follow him on SU, ClearVoice, About me, Science Publishing Group, ORCID, My Science Work, Smashwords, Twitter, and Google Scholar.